Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Nanobiotix (5NRA) Stock Price & Analysis

0 Followers

5NRA Stock Chart & Stats

€28.20€1.20(8.46%)
At close: 5:30 PM GMT+1
€30€32.5€35Jun 17Jul 20Aug 26Sep 10
Day’s Range
EUR 28.20 - EUR 28.60
52-Week Range
EUR 16.60 - EUR 47.40
Previous Close
EUR 26.00
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 1.48B
Enterprise Value
EUR 1.84B
Total Cash (Recent Filing)
EUR 110.85M
Total Debt (Recent Filing)
EUR 106.57M
Price to Earnings (P/E)
―
Beta
0.01
Next Earnings
Apr 27, 2027 (Est.)
EPS Estimate
0.05
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Validation

The melanoma study provides meaningful clinical validation for NBTXR3 in a heavily pre-treated, anti-PD-1-resistant population. Reported responses, disease control, safety, and survival signals support progression into randomized trials and could strengthen the platform’s partnering and commercialization prospects.

Platform Expansion Potential

Activity in both injected and non-injected lesions supports the company’s strategy of combining local nanoparticle treatment with radiotherapy and immunotherapy. The exploratory immune findings also suggest potential applicability across tumor settings, although further trials are required.

Partnering-based Funding Model

The Janssen relationship gives Nanobiotix a route to fund development and potentially participate in future commercialization economics without relying solely on direct product sales. Milestones, royalties, and profit-sharing could improve strategic reach if clinical and regulatory objectives are achieved.

Bears Say

Persistent Unprofitability

The recent revenue rebound has not translated into sustainable profitability. Recurring EBIT, EBITDA, and net losses indicate that Nanobiotix still needs substantial development investment before its business model can support itself through earnings, leaving results sensitive to funding and partnering outcomes.

Ongoing Cash Burn

Persistent operating and free-cash-flow deficits show that Nanobiotix is consuming cash to sustain research and clinical development. Continued dependence on external funding can constrain investment flexibility and create financing pressure if milestones, partnerships, or commercialization progress take longer than expected.

Weak Capitalization

Negative equity and debt exceeding total assets represent a material deterioration in capitalization and limit financial flexibility. Elevated leverage may increase the company’s dependence on new financing or strategic funding, while reducing its ability to absorb setbacks in clinical development or regulatory execution.

Nanobiotix News

5NRA FAQ

What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was €16.60 and its highest was €47.40 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is €1.48B.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s next earnings report is estimated for Apr 27, 2027 (not yet confirmed), which is in 166 days.
How were Nanobiotix’s earnings last quarter?
Nanobiotix released its earnings results on Sep 24, 2026. The company reported -€0.699 earnings per share for the quarter, missing the consensus estimate of -€0.258 by -€0.44.
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is 0.05.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 50,967,610 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Nanobiotix reported an EPS of -€0.699 in its last earnings report, missing expectations of -€0.258. Following the earnings report the stock price went down -2.113%.
Which hedge fund is a major shareholder of Nanobiotix?
Hedge funds hold Nanobiotix shares: the largest hedge-fund position in Nanobiotix is 1,175,779,722 shares, and hedge funds decreased their holdings by 105.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology